Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study
Hakan Kocoglu1, Mustafa Karaca2, Deniz Tural3, Erhan Hocaoglu2, Yildiz Okuturlar1, Zeynep Fetullahoglu1, Meral Gunaldi3, Rumeysa Ciftci3, Savas Tuna3, Orhan Kemal Yuce4, Gulsum Ozet5, Ahmet Ozet2, Mustafa Benekli2
1 Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
2 Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
3 Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
4 Department of Hematology, Akdeniz University Faculty of Medicine, Antalya, Turkey
5 Department of Hematology, Ankara Numune Education and Research Hospital, Ankara, Turkey
Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Zuhuratbaba District, Tevfik Saglam Street, No. 11, 34147 Bakirkoy, Istanbul
Source of Support: None, Conflict of Interest: None
Objective: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are associated with significant morbidity and mortality among cancer patients who received cytotoxic chemotherapy. The aim of current study was to elucidate the prevalence of HBV and HCV among large population of solid cancers and lymphoma and to compare them with large number of control group.
Patients and Methods: Between 2000 and 2014, 8322 cancer patients who were admitted to Oncology Departments were evaluated retrospectively and 3890 patients in whom hepatitis serology were available were included in this study. Their results were compared with control group that consisted of 96,000 subjects.
Results: In control groups, hepatitis B surface antigen (HBsAg) positivity rate was 3.3% and anti-HCV positivity rate was 0.84%. In cancer patients, HBsAg positivity rate was 3.65% and anti-HCV positivity rate was 1.2%. Neither HBsAg positivity rate nor anti-HCV positivity rate was statistically significant between groups (P = 0.12 and P = 0.09, respectively). HBsAg positivity rates of head and neck cancer (5.88%; P = 0.02), rectum (5.6%; P = 0.025), and gastric and esophagus cancer (5.88%; P = 0.025) were significantly higher than control groups. Anti-HCV positivity rate (2.5%; P = 0.0016) was significantly higher in lung cancer when compared with control group.
Conclusion: The current study elucidated the prevalence of HBV and HCV among large population of solid cancers and lymphoma and we showed that hepatitis B and C positivity rates are significantly increased in certain solid tumors. Our findings should also be clarified with large prospective studies.